SIMPLE DOSING WITH XOFIGO¹
Xofigo should be received, used, and administered only by authorized persons in designated clinical settings.
Injections take place every 4 weeks.
XOFIGO IS DELIVERED IN A CONVENIENT, PATIENT-READY DOSE
- A patient-ready dose with the requested activity will be provided in a syringe by Cardinal Health Nuclear Pharmacy Services2
- The patient-ready dose is 1.49 microcurie (55 kBq) per kg body weight1a
The volume to be administered to a given patient is calculated as follows1a:
Note: This is for your information only. Cardinal Health will perform all calculations for your convenience.
- The shelf life of Xofigo in the patient-ready syringe is 96 hours3
- Xofigo is a ready-to-use solution and should not be diluted or mixed with any other solutions1
Assay the dose immediately before treatment, and set up the infusion environment by placing absorbent materials in the area where the injection will take place1
Insert the IV cannula required by your institution for injection. Connect a 2- or 3-way stopcock to the IV device, and then open the stopcock to flush the infusion set with isotonic saline to confirm IV patency
If IV patency is confirmed, remove the red cap from the Xofigo syringe and attach the open port of the stopcock. Then, turn the stopcock so that it is closed to the saline syringe and open from the Xofigo syringe to the patient
Administer Xofigo by slow IV injection over 1 minute. When complete, turn the stopcock to shut off the Xofigo syringe and open the saline syringe. Flush the infusion system thoroughly with isotonic saline, remove the syringes and injection setup, and assay immediately for residual activity. Dispose of according to institutional policies1
After administration of Xofigo, the patient should remain in the office for a period of time determined by institutional policies to ensure there are no complications from administration. Fill out the Xofigo Patient Release Card and give it to him before he leaves.
FOLLOW APPROPRIATE DRUG HANDLING1
- Xofigo should be received, used, and administered only by authorized persons in designated clinical settings. The receipt, storage, use, transfer, and disposal of Xofigo are subject to the regulations and/or appropriate licenses of the competent official organization
- Follow normal working procedures for the handling of radiopharmaceuticals, and use universal precautions, such as gloves and barrier gowns, when handling blood and bodily fluids to avoid contamination
- In case of contact with skin or eyes, flush immediately with water
- If spillage occurs, contact the local radiation safety officer immediately to initiate necessary measurements and required procedures to decontaminate
- 0.01 M EDTA solution is recommended to remove contamination
If you have questions, request assistance from a Bayer representative.
EDTA=Ethylene-Diamine-Tetraacetic Acid; IV=Intravenous.
aBased on the 2015 standard set by National Institute of Standards and Technology (NIST), the numerical description of the patient dose has been adjusted from 50 kBq/kg to 55 kBq/kg of body weight and the numerical description of the radioactivity in the vial has been changed from 1000 kBq/mL to 1100 kBq/mL.2
- Xofigo® (radium Ra 223 dichloride) injection [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; December 2019. Return to content
- United States Nuclear Regulatory Commission. Revision to the National Institute of Standards and Technology standard for radium-223 and impact on dose calibration for the medical use of radium-223 dichloride. http://pbadupws.nrc.gov/docs/ML1526/ML15264B095.pdf. Accessed March 11, 2016. Return to content
- Data on file. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2016. Return to content